Phase 3Recruiting
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Sponsored by Hoffmann-La Roche
About this study
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
Enrolling at this location
Accel Research Sites-NeuroStudies
Decatur, Georgia
I'm interestedThis study also enrolls at 34 other locations. See all.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.